37-PUB: Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors among Pregnant Women with Diabetes at Time of Conception Stratified by Socioeconomic Factors

Introduction and Objective: Glucagon Like Peptide-1 Receptor Agonists (GLP-1) and Sodium Glucose Cotransporter 2 Inhibitors (SGLT2-i) are not approved for use in the immediate pre-pregnancy period. The aim of this study was to determine the prevalence of use of GLP-1 RA/SGLT2i in pregnant patients at time of conception among women with and without any type of diabetes mellitus (DM) by race/ethnicity and health insurance. Methods: ICD-10 codes were used to analyze data of pregnant women with and without a diagnosis of diabetes mellitus who gave birth at Sutter Health, a large integrated healthcare system in Northern California between 5/1/2023 and 6/30/2024. We stratified those who were prescribed a GLP-1RA/SGLT2i by race/ethnicity and insurance type. Descriptive and chi-squared statistics were used to identify statistically significant differences. Results: Among 49,781 women, 9,800 (19.6%) who gave birth had DM. Results by race/ethnicity are shown in the table. 65% of women using a GLP1/SGLT2i had DM. AIAN/NHOPI (5.7%) and Black/African American, Hispanic (2.1%) women had higher prescription rate. More than half (55.7%) with a prescription had commercial insurance. Conclusion: Few pregnant women (1.7%) with a DM diagnosis captured were taking a GLP-1RA or SGLT2i near or at the time of conception. Use of the medications in women pre-pregnancy align with rates of diabetes and obesity across racial and ethnic groups at Sutter Health. Disclosure M. Antuna: None. D. Kerr: Stock/Shareholder; Current; Glooko, Inc. Research Support; Current; Abbott Diabetes. K. Hays: None. Y. Guo: None. F. Farrokhi: None. R. Lane: None.